menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Clinically meaningful benefits with GLP-1RA in HFpEF and obesity

Clinically meaningful benefits with GLPRA in HFpEF and obesity
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    ESC Congress 2023 The STEP HFpEF trial shows that semaglutide improves HF-related symptoms and leads to greater weight loss in patients with HFpEF. “Collectively, these findings indicate that semaglutide is a valuable treatment option in patients with HFpEF and obesity” says Mikhail Kosiborod.

  • Educational information

    This video was recorded during the ESC Congress 2023 in Amsterdam, The Netherlands

  • Faculty

    Mikhail Kosiborod, MD is a Cardiologist and Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of the STEP HFpEF study

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    ESC Congress 2023 The STEP HFpEF trial shows that semaglutide improves HF-related symptoms and leads to greater weight loss in patients with HFpEF. “Collectively, these findings indicate that semaglutide is a valuable treatment option in patients with HFpEF and obesity” says Mikhail Kosiborod.

  • Educational information

    This video was recorded during the ESC Congress 2023 in Amsterdam, The Netherlands

  • Faculty

    Mikhail Kosiborod, MD is a Cardiologist and Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of the STEP HFpEF study

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Schedule24 May 2024